Jacobs Levy Equity Management, Inc Nektar Therapeutics Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 3,007,928 shares of NKTR stock, worth $71 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,007,928
Previous 2,626,961
14.5%
Holding current value
$71 Million
Previous $2.44 Million
16.29%
% of portfolio
0.01%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding NKTR
# of Institutions
96Shares Held
83.7MCall Options Held
1.18MPut Options Held
64.6K-
Black Rock Inc. New York, NY15.2MShares$358 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.79MShares$184 Million0.24% of portfolio
-
Eventide Asset Management, LLC Boston, MA6.65MShares$157 Million0.1% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.7MShares$111 Million0.01% of portfolio
-
Almitas Capital LLC Santa Monica, CA4.61MShares$109 Million1.77% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $4.42B
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...